Skip to main content
. 2022 Aug 3;14:17588359221116604. doi: 10.1177/17588359221116604

Figure 2.

Figure 2.

One-way sensitivity analysis in all randomized patients (A).

C, pemetrexed plus cisplatin/carboplatin; ICER, incremental cost-effectiveness ratio; NI, nivolumab plus ipilimumab; P, probability; PD, progressive disease; PFS, progression-free survival.